MedPath

Congenital hemolytic anemia: causes, symptoms and consequences

Recruiting
Conditions
congenital hemolytic anemia, anemia, hereditary hemolytic anemia, sickle cell disease, thalassemia, pyruvate kinase deficiency, G6PD, spherocytosis.(Congenitale hemolytische anemie, anemie, sikkelcel ziekte, thalassemie, PKD, G6PD, sferocytose)
Registration Number
NL-OMON22083
Lead Sponsor
niversity Medical Center, Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
100
Inclusion Criteria

Adult patients who meet the criteria of non-immune mediated hemolytic anemia in whom acquired causes have been excluded in the diagnostic track. Such patients can be subdivided into 4 main categories:

1. red cell membrane disorders, e.g. hereditary spherocytosis

Exclusion Criteria

Inability to give informed consent

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To create insight in current disease burden by creating a descriptive cohort of patients, diagnosed with rare congenital hemolytic anemia.<br /><br>Points of interest are:<br /><br>- Prevalence and incidence of disease<br /><br>- Quality of life<br /><br>- Prevalence and incidence of iron overload<br /><br>- Prevalence and incidence of comorbidities and related silent organ damage<br /><br>- Prevalence and incidence of splenectomy and complications<br>
Secondary Outcome Measures
NameTimeMethod
To further analyze the pathophysiology of congenital hemolytic anemia: to perform a case control study comparing patient parameters and healthy control parameters. <br /><br>Parameters of interest are:<br /><br>1. The tolerability of low hemoglobin levels in rare congenital hemolytic anemia patients.<br /><br>2. Patterns in laboratory parameters: pro-inflammatory profile, Red blood cell characteristics, microparticle analysis, and markers of coagulation activation.<br /><br>3. RNA seq parameters for peripheral blood mononuclear cell transcriptome mapping using blood sample analysis and then compare and relate outcome to other results of the study. <br>
© Copyright 2025. All Rights Reserved by MedPath